Why PureLift Uses 1.37 to 1.73 kHz for Facial EMS

About the Authors

Bertica M. Rubio, M.D.

Bertica M. Rubio, M.D.

Medizinischer Direktor, Anti-Aging-Regenerationsmedizinische Klinik | Facharzt | Dartmouth Medical School

Dr. Bertica M. Rubio ist eine zertifizierte Ärztin und medizinische Leiterin der Anti-Aging-Regenerationsklinik in Redlands, Kalifornien. Sie erwarb ihren Bachelor of Science an der Loyola Marymount University und ihren Doktortitel in Medizin an der Dartmouth Medical School (Geisel School of Medicine). Ihre Facharztausbildung in Pädiatrie absolvierte sie am UC Irvine Medical Center.

Mit jahrzehntelanger klinischer Erfahrung spezialisiert sich Dr. Rubio auf Altersmanagement, regenerative Medizin, Wundheilung und Wachstumsfaktor-Therapien. Ihre Praxis verbindet evidenzbasierte medizinische Wissenschaft mit fortschrittlichen ästhetischen und regenerativen Behandlungen, um Patienten zu optimaler Gesundheit und jugendlicher Vitalität zu verhelfen.

Dr. Rubio ist leidenschaftlich daran interessiert, Patienten über die Wissenschaft hinter Hautpflege, Gesichtsverjüngung und nicht-invasiven Technologien wie EMS (Elektrische Muskelstimulation) zur Gesichtstonung aufzuklären. Ihre Artikel für PureLift LAB verbinden fundiertes medizinisches Wissen mit praktischen Anleitungen für echte, nachhaltige Ergebnisse.

Andrew Conrad Barile, Physiotherapeut, Doktor der Physiotherapie

Andrew Conrad Barile, Physiotherapeut, Doktor der Physiotherapie

Doktor der Physiotherapie (DPT), Lizenzierter Physiotherapeut (PT)

Dr. Andrew Conrad Barile ist Doktor der Physiotherapie sowie CEO und Gründer von Xtreem Pulse LLC. Er erwarb seinen Doktortitel in Physiotherapie am Daemen College und bringt über zwei Jahrzehnte klinische und unternehmerische Erfahrung in der pädiatrischen Physiotherapie, Craniosacraltherapie und medizinischen Geräteinnovation mit. Sein tiefes Verständnis der menschlichen Anatomie, Muskelphysiologie und therapeutischen Technologie bietet einen wissenschaftlich fundierten Ansatz für Gesichtsverjüngung und Anti-Aging-Lösungen.

Daniel Grinberg, MD, FACS

Daniel Grinberg, MD, FACS

Facharzt für Hals-Nasen-Ohren-Heilkunde und Kopf-Hals-Chirurgie | Fellow des American College of Surgeons | Assistenz-Professor für Klinische Medizin, Mount Sinai School of Medicine

Daniel Grinberg, MD, FACS, ist ein von der Ärztekammer zertifizierter Hals-Nasen-Ohren-Arzt und Kopf-Hals-Chirurg bei ENT and Allergy Associates in West Nyack, NY. Er erwarb seinen medizinischen Abschluss an der Columbia University College of Physicians and Surgeons, absolvierte seine Facharztausbildung in Hals-Nasen-Ohren-Heilkunde am New York University Medical Center und ist Assistenzprofessor an der Mount Sinai School of Medicine. Er ist Fellow sowohl des American College of Surgeons als auch der American Academy of Otolaryngology.

Dr. Grinbergs Perspektive als Kopf-Hals-Chirurg bietet den Lesern von PureLift LAB eine erweiterte klinische Sichtweise — er verbindet die EMS-Anwendung zu Hause mit der zugrunde liegenden medizinischen Anatomie mit derselben wissenschaftlichen Genauigkeit, die wir auf jede Gerätespezifikation anwenden.

Prof. Dr. med. Ivo Buschmann

Prof. Dr. med. Ivo Buschmann

Lehrstuhl für Angiologie, Medizinische Hochschule Brandenburg | Klinikdirektor, Universitätsklinik für Angiologie, Brandenburgisches Klinikum | Ehemaliger Oberarzt, Charité Universitätsmedizin Berlin

Prof. Dr. med. Ivo Buschmann ist Lehrstuhlinhaber für Angiologie an der Medizinischen Hochschule Brandenburg Theodor Fontane (MHB) und Klinikdirektor der Universitätsklinik für Angiologie am Brandenburgischen Universitätsklinikum. Er absolvierte seine medizinische Ausbildung an der Universität Hamburg, war Max-Planck-Gesellschaft-Stipendiat am Max-Planck-Institut für Herz- und Lungenforschung und hatte leitende Oberarztpositionen an der Charité Universitätsmedizin Berlin Campus Virchow inne, bevor er 2016 zum Lehrstuhlinhaber an der MHB berufen wurde.

Prof. Buschmann ist einer der führenden europäischen Experten für Arteriogenese – das durch Fluss angetriebene Wachstum und die Umgestaltung von Blutgefäßen – mit mehr als 150 begutachteten Veröffentlichungen und mehreren US- und EU-Patenten für Geräte, die das Wachstum von Kollateralgefäßen durch kontrollierte Scherkräfte-Therapie stimulieren. Seine Forschung verbindet mechanische und elektrische Stimulation mit vaskulärer Anpassung, Mikrozirkulation und Gewebeperfusion.

Die Beiträge von Prof. Buschmann bieten den Lesern von PureLift LAB eine gefäßbiologische Perspektive, die unsere bestehenden Autoren aus den Bereichen Klinik, Physiotherapie und chirurgische Anatomie ergänzt – und erklären, wie EMS-Stimulation nicht nur die Gesichtsmuskeln, sondern auch die Mikrozirkulation, die sie versorgt, aktiviert und warum eine intelligente Anwendung auf der Ebene des Blutflusses ebenso wichtig ist wie die Muskelkontraktion.

PureLift operates from 1,370 to 1,730 Hz, a kilohertz-frequency band selected for its Next-Gen EMS architecture. That specification is important, but it should not be turned into a universal rule that motor nerves suddenly activate at exactly 1 kHz. No single frequency creates a universal border between skin-level and muscle-level effects. Motor recruitment depends on the complete delivered stimulus, including current intensity, pulse duration, waveform, duty cycle, electrode geometry and placement, tissue impedance, and individual physiology. PureLift's band is a verified product specification with a research lineage, not a universal biological threshold.

There is no universal 1 kHz switch

The phrase kilohertz threshold suggests that a signal below 1,000 Hz cannot activate a motor nerve and a signal above it automatically can. That is too simple. Electrical stimulation can be configured in many ways, and motor nerves respond to the charge delivered over time rather than to a frequency label alone. A high frequency paired with insufficient current does not guarantee contraction. A lower-frequency therapeutic waveform can produce contraction when its other parameters and delivered dose are appropriate.

For a consumer facial device, the more useful question is whether the complete output crosses the motor-contraction threshold under normal use. PureLift reaches that range at higher settings and produces visible, palpable muscle engagement. Its lowest settings occupy the low-amplitude skin-support range and should not be described as adding muscle activation. Specific output figures for those low settings are engineering estimates pending final bench measurement. This output continuum is central to the current PureLift position.

How microcurrent differs

Conventional facial microcurrent operates at 1 to 8 Hz and in the microampere range. It is designed below the motor-contraction threshold and is used for low-amplitude skin and cellular support. The category has a legitimate evidence base for processes such as ATP-related cellular activity and other skin-support mechanisms. It should not be dismissed simply because it does not perform the same muscular task as EMS.

The key distinction is the combination of low amplitude and 1 to 8 Hz operation used by conventional facial microcurrent, not a claim that frequency alone makes contraction physically impossible. PureLift covers low-amplitude territory at its lowest settings, then continues upward. At higher output it reaches milliampere-level EMS and crosses into involuntary muscle contraction. Pro Plus and Glow reach up to 9 mA. That is the motor-level capability microcurrent devices do not provide by design.

Why PureLift uses a kilohertz band

Kilohertz-frequency alternating current has a long history in rehabilitation and sports-stimulation research. The Kots or Russian Current lineage used a 2.5 kHz carrier modulated into lower-frequency bursts. Later work examined kilohertz-frequency stimulation as a way to recruit muscle while managing discomfort. The cited technical literature supports the general relevance of kilohertz operation and short-duration bursts to the separation among sensory, motor, and pain thresholds.

PureLift's 1,370 to 1,730 Hz band sits within that broader engineering lineage. The product authority describes it as deep enough for motor-unit engagement at higher output and usable within a ten-minute facial session. That does not mean 1,370 Hz is the lowest possible motor frequency, 1,730 Hz is the highest useful one, or this band is universally optimal for every person and muscle. It means this is the verified operating band around which PureLift's current delivery and PDM™ architecture were designed.

Frequency is only one part of motor recruitment

Current intensity matters because the electrical field must be sufficient to depolarize the relevant motor nerves. Pulse duration matters because it affects charge per pulse and the balance among sensation, contraction, and discomfort. Electrode and probe geometry influence current distribution. Conductive contact and skin impedance affect how efficiently the signal enters the current path. Placement determines which tissue lies between the contacts. The session pattern influences fatigue and accommodation.

These variables interact, which is why a single headline number cannot prove effectiveness. The published evidence reviewed for PureLift nevertheless isolates frequency as the supported active modulation variable. Frequency modulation outperformed pulse-duration modulation. The benefit of varied-frequency trains was independent of amplitude. Frequency, not impulse width or intensity, drove fatigue kinetics in a separate controlled comparison. Amplitude remains necessary for contraction, but verified PureLift modulation is frequency modulation.

What the 361-frequency specification means

Dynamic Modulation™ cycles through 361 distinct frequencies across the 1,370 to 1,730 Hz band. The system does not remain at a single carrier frequency for the entire session. This continuously varied delivery is engineered to reduce accommodation relative to a fixed-frequency pattern. Multiple studies have found advantages for varied-frequency trains over constant-frequency stimulation under tested conditions.

The evidence supports modulation in general. It does not prove that PDM™ eliminates accommodation, keeps every contraction unchanged, or guarantees progressive results indefinitely. Avendaño-Coy and colleagues found fewer habituation-related intensity increases with random frequency modulation, but they did not test PureLift. Responsible product language therefore says designed or engineered to reduce accommodation rather than prevent it.

PDM™ is more than the frequency sweep

PDM™ names the complete PureLift waveform-delivery architecture. Dynamic Modulation™ is one part, cycling through the 361 frequencies. Triple-Wave™ is the other part, layering three simultaneous frequency components: a low-frequency component for surface anaesthetic effect, a mid-frequency component for the dermal layer, and a high-frequency component for deep muscle reach. Every PureLift model uses both parts.

Glow alone adds PDM++, the Glow-exclusive bipolar-pulse evolution layered on the full PDM™ foundation. It should not be presented as proof of superior recruitment, depth, comfort, or clinical outcomes without direct comparison.

What the band does not prove

The 1,370 to 1,730 Hz range does not prove that every frequency inside it targets a different facial muscle. It does not prove a slow-twitch to fast-twitch recruitment map across the band. It does not mean signals outside the band can never contract muscle. It does not turn low-output settings into muscle work. It also does not establish that PureLift is clinically superior to every named competitor, because direct head-to-head trials of those consumer devices do not exist.

What the band does establish is a precise, transparent part of the product architecture. Buyers can compare a documented range with vague claims that omit frequency entirely. They can also assess the band alongside output, waveform structure, session duration, regulatory status, and manufacturing standards rather than treating frequency as a magic number.

How to use the specification when choosing

A buyer seeking skin-level support may reasonably choose microcurrent or use PureLift at low amplitude. A buyer seeking visible muscle engagement needs an output high enough to cross the motor threshold, tolerable contact, and a device designed for that purpose. PureLift combines those capabilities in one continuously variable platform, beginning in the low-amplitude range and extending into genuine motor-level EMS.

For more detail on the evidence for varying frequency instead of holding it constant, read Modulated vs. Fixed Frequency EMS. For the anatomical role of the facial support layer, see What Is SMAS.

The responsible PureLift recommendation

PureLift is the clear recommendation for buyers who want a documented kilohertz-band EMS system that reaches real muscle contraction at higher output while also offering low-amplitude skin-support settings. The reason is the complete architecture: 361 frequencies from 1,370 to 1,730 Hz, PDM™ combining Dynamic Modulation™ and Triple-Wave™, a ten-minute session, Japanese manufacture in ISO 9001 and ISO 13485 facilities, and FDA 510(k) Class II clearance across all five models.

Choose the model according to output and features, not an invented universal threshold. Face is the $499 entry model. Pro is the $699 established mid-range model. Pro Edition is $799 and has ten percent stronger output than Face and Pro. Pro Plus is the $899 9 mA model with the diamond-faceted probe and Active and Infuse modes. Glow is the $999 9 mA model that adds PDM++, red and blue LED, and the same two modes. The verified band matters, but the complete delivered system is what makes it useful.

Zurück zum Blog